Bayer’s HYRNUO Wins FDA Approval for HER2-Mutated Lung Cancer
Bayer AG (ETR: BAYN) announced that sevabertinib (trade name HYRNUO) received U.S. FDA approval for...
Bayer
Bayer Reports Stable Q3 2025 Sales, Highlights Strong Nubeqa and Kerendia Growth
Bayer AG (ETR: BAYN) announced on November 12 2025 that its third‑quarter 2025 (2025Q3) performance matched prior‑year...
Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS
Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval...
Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to €260 Million
Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA)...
Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor
German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August...
Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing...
Bayer and JD Health Collaborate on Dulcolax-Lactulose to Expand China’s Digestive-Health Market
Bayer (ETR: BAYN) and JD Health (HKG: 6618) have launched Dulcolax-branded lactulose in a pioneering...
Bayer AG’s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction ≥40%
German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from...
Bayer’s Elinzanetant Granted UK Marketing Authorization for Menopause-Related Vasomotor Symptoms
Germany’s Bayer (ETR: BAYN) this week announced that the UK Medicines and Healthcare products Regulatory...
Bayer and Tsinghua University Renew Strategic Research Pact for Drug Innovation
German pharmaceutical giant Bayer AG (ETR: BAYN) and Tsinghua University announced the signing of their...
Bayer’s Nubeqa Receives Positive CHMP Opinion for mHSPC Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced last week that the European Medicines Agency...
ADVANZ PHARMA Acquires Bayer’s Testoviron Commercial Rights in Key Markets
UK-based ADVANZ PHARMA announced the acquisition of commercial rights to testoviron from German giant Bayer...
Bayer Wins Beijing MPA Approval for MEDRAD Stellant D-CE Medical Device
German giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from the...
Bayer Files NDA for Gadoquatrane, Aiming to Offer Lowest-Dose GBCA in the U.S.
Germany-based Bayer AG (ETR: BAYN) announced that it has made a New Drug Application (NDA)...
Bayer Extends Genomics Partnership With Broad Institute for Cardiology Research
German pharmaceutical giant Bayer AG (ETR: BAYN) and the US-based Broad Institute Inc. announced a...
Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD
German pharmaceutical giant Bayer AG (ETR: BAYN) announced results from the Phase II CONFIDENCE study,...
Bayer’s Vividion Gains Global Rights to WRN Inhibitor VVD-214
German pharmaceutical giant Bayer AG (ETR: BAYN) announced that its wholly owned subsidiary Vividion Therapeutics,...
Bayer’s Nubeqa Gets FDA Approval for mHSPC Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration...
Bayer Files for Approval of Gadoquatrane MRI Contrast Agent in Japan
German pharmaceutical giant Bayer AG (ETR: BAYN) this week filed a marketing application with Japan’s...
Bayer’s Sevabertinib Receives FDA Priority Review for HER2-mutant NSCLC
German pharmaceutical giant Bayer AG (ETR: BAYN) announced that its investigational oral small-molecule tyrosine kinase...